Methionine Synthase Reductase A66G Polymorphism is not Associated with Breast Cancer Risk

Introduction & Aim: Breast cancer is the most frequent cancer among women in word. Breast cancer is a heterogeneous and complex disease. Several factors including genetic and environmental factors are associated with the breast cancer development. Because of folate and one-carbon metabolism play crucial role in nucleotide and DNA synthesis, several study suggested One-carbon metabolism play crucial role in breast cancer risk. We conducted a case-control study to investigate the association between MTRRA66G polymorphism and breast cancer risk.Method: A matched case-control study consisted of 100 breast cancer patients who were newly diagnosed and 144 controls were performed. Genotyping of MTRRA66G was performed by allele specific PCR method Results: The frequency of MTRR 66G genotype in patients (49%) was not significantly different than that in controls (51%, p=0.65). We found that MTRRA66G polymorphism was not associated with breast cancer risk. Conclusion: In this study, our finding suggested that MTRRA66G polymorphism was not associated with the risk of breast cancer in Kermanshah population